The CFO expects high single-digit sales growth for Primatene Mist in 2025, while Glucagon may see declines due to competition. If AMP 007 and AMP 018 are approved in Q2, they plan to launch in Q3.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay